Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: Current data on safety and efficacy

Madhav Desai; Kate J. Newberry; Jorge Romaguera; Liang Zhang; Zhishuo Ou; Michael Wang

doi:10.1186/1756-8722-6-55

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: Current data on safety and efficacy

Madhav Desai, Kate J. Newberry, Jorge Romaguera, Liang Zhang, Zhishuo Ou, Michael Wang

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.

Original language	English (US)
Article number	55
Journal	Journal of Hematology and Oncology
Volume	6
Issue number	1
DOIs	https://doi.org/10.1186/1756-8722-6-55
State	Published - 2013
Externally published	Yes

Keywords

B-cell
Immunomodulatory
Lenalidomide
Lymphoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1186/1756-8722-6-55

Find It

Find It at U of M Libraries

Cite this

@article{7abd12b6d76c462884f931186a38b099,

title = "Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: Current data on safety and efficacy",

abstract = "Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.",

keywords = "B-cell, Immunomodulatory, Lenalidomide, Lymphoma",

author = "Madhav Desai and Newberry, {Kate J.} and Jorge Romaguera and Liang Zhang and Zhishuo Ou and Michael Wang",

year = "2013",

doi = "10.1186/1756-8722-6-55",

language = "English (US)",

volume = "6",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma

T2 - Current data on safety and efficacy

AU - Desai, Madhav

AU - Newberry, Kate J.

AU - Romaguera, Jorge

AU - Zhang, Liang

AU - Ou, Zhishuo

AU - Wang, Michael

PY - 2013

Y1 - 2013

N2 - Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.

AB - Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.

KW - B-cell

KW - Immunomodulatory

KW - Lenalidomide

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84880872904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880872904&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-6-55

DO - 10.1186/1756-8722-6-55

M3 - Review article

C2 - 23915913

AN - SCOPUS:84880872904

SN - 1756-8722

VL - 6

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 55

ER -

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: Current data on safety and efficacy

Abstract

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this